

## **Online Supplementary Material**

Validation of a Model Estimating the Budget Impact of Video Capsule Endoscopy for Surveillance of Crohn's Disease in an Italian Center. *JHEOR*. 2024;11(1):67-74. <u>doi:10.36469/jheor.2024.92880</u>

Table S1: Markov Model Transition Probability

Table S2: Crohn's Disease Location Transitions

Table S3: Cost Inputs

Table S4: Permissive and Restrictive Outcome Definitions

Figure S1: One-Way Sensitivity Analysis

## Figure S2: Flow Plan of the Analysis

This supplementary material has been provided by the authors to give readers additional information about their work.



## Table S1. Markov Model Transition Probability

Markov Model States	Undiagnosed CD	Remission	Non-Active Symptomatic	Active Symptomatic	Active Nonsymptomatic	GI Hemorrhage	Treatment	Treatment Failure	Surgery	Post- surgery	Death
Undiagnosed CD	0.725660555	0	0	0	0.011904762	0	0.2420711	0	0.020363614	0	0
Remission	0	0.823549	0.058816991	0.058816991	0.058816991	0	0	0	0	0	0
Non-active symptomatic	0	0.1647927	0.534319235	0.058816991	0	0	0.2420711	0	0	0	0
Active symptomatic	0	0.1647927	0.013678085	0.379475333	0.164792705	0.01482649	0.2420711	0	0.020363614	0	0
Active non-symptomatic	0	0.1647927	0	0.164792705	0.623319724	0.01482649	0.0119048	0	0.020363614	0	0
GI hemorrhage	0	0	0	0	0	0	0.8	0	0.2	0	0
Treatment	0	0.0599244	0	0	0	0	0.7680927	0.171982879	0	0	0
Treatment failure	0	0	0	0	0	0	0.9796364	0	0.020363614	0	0
Surgery	0	0	0	0	0	0	0	0	0	1	0
Post-surgery	0	0.127316	0	0	0.07884413	0	0.6453102	0	0.148529659	0	0
Death	0	0	0	0	0	0	0	0	0	0	1

Abbreviations: CD, Crohn's disease; GI, gastrointestinal.

Table S2. Crohn's Disease Location Transitions				
Location Transitions	L1	L2	L3	L4
L1	0.963333235	0.0122223	0.012222255	0.012222255
L2	0	0.98890807	0.005545966	0.005545966
L3	0	0	0.996986405	0.003013595
L4	0	0	0	1

Table S3. Cost Inputs

Table 55. Cost inputs			
Item	Costs € (DRG code)		
Ileocolonoscopy, per procedure	74.00 (45.23) <sup>28</sup>		
VCE, per procedure	850.00 (45.13.1) <sup>28</sup>		
Patency capsule, per procedure	133.8329		
MRE, per procedure	160.10 (88.95.4) <sup>28</sup>		
Fecal calprotectin test, per procedure	12.05 (90.12.A Veneto) <sup>30</sup>		
CRP test	5.00 (90.72.3) <sup>28</sup>		
Infliximab, per year	12254.40ª		
Infliximab, administration cost	10.65 (99.25) <sup>28</sup>		
Adalimumab, per year	10197.29ª		
Adalimumab, administration cost	8.50 (99.29.5) <sup>1</sup>		
Vedolizumab, per year	15 349.06ª		
Vedolizumab, administration cost	10.65 (99.25) <sup>1</sup>		
5-ASA, per year	10.96ª		
5-ASA, administration cost	_		
Corticosteroids, per year	29.22ª		
Corticosteroids, administration cost	_		
Azathioprine, per year	255.68ª		
Azathioprine, administration cost	_		
Open bowel surgery	7611.36 <sup>2</sup>		
Abscess drainage	4812.69 (171) <sup>2</sup>		
Fistula repair	5514.36 (156) <sup>2</sup>		
Stricturing repair	4805.04 (153) <sup>2</sup>		
Capsule retention	914.83 (189) <sup>2</sup>		
Bowel perforation	914.83 (189) <sup>2</sup>		

Abbreviations: ASA, 5-aminosalicylic acid; CRP, C-reactive protein; MRE, magnetic resonance enterography; VCE, video capsule endoscopy. aBiologics and conventional annual costs from 2023 wholesale prices.

## REFERENCES


1. Regione Emilia Romagna. PRESTAZIONI DI ASSISTENZA SPECIALISTICA AMBULATORIALE, ottobre 2022. Accessed September 19, 2023. <u>https://salute.regione.emilia-romagna.it/ssr/strumenti-e-informazioni/nomenclatore-tariffario-rer/ottobre-2022</u>

2. Regione Emilian Romagna. DRG 2023 - 878.

Table S4. Permissive and Restrictive Outcome Definitions						
		Biologics	Surgery	Remission		
Permissive	Model Continuous 6-month use (2 consecutive intervals)		Keep all (fistulectomy, emergency, elective)	Consecutive 6-month period CDAI ≤150		
	RWD	Continuous 6-month use (1 interval)	All non-missing	Any 6 months CDAI ≤ 150		
Restrictive	Model	Minimum 1-year continuous use (4 consecutive intervals)	Keep only elective and emergency surgery (state "i")	Consecutive 1-year period CDAI ≤150		
	RWD	Minimum 1-year continuous use (2 consecutive intervals)	Drop fistulectomies (keep only "yes")	Consecutive 1-year period CDAI ≤150		

Abbreviation: RWD, real-world data.


Figure S1. One-Way Sensitivity Analysis



This figure presents the impact of a ±20% variation in relevant cost inputs on the base case results (5-year total cost difference between standard of care and VCE). Positive values favor VCE.

Abbreviations: CT, computer tomography; MRE, magnetic resonance enterography; VCE, video capsule endoscopy.

Figure S2. Flow Plan of the Analysis



Flow plan shows analysis from acquiring pseudonymized real patient data to comparing outcomes with model-generated data on patients after applying selection criteria.